Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
AK

NASDAQ · AKTS

Aktis Oncology, Inc.

Healthcare · Biotechnology

$17.86

Down-$0.66 (-3.56%)

Updated Oct 7, 2026, 4:34 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.06B
P/E ratio
0
Dividend yield
0.00%
52-week range
$0.03 – $34.19
Volume
294.76K
Avg. volume
374.39K

Price performance · AKTS

AKTS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

AKTS closed at $17.86 after 21 trading sessions, down 28.62% for the selected period.

Last close
$17.86
Period change
-28.62%
Period low
$17.86
Period high
$25.02
Daily close
View OHLC price history
AKTS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$18.64$18.75$17.81$17.86294.76K
Oct 5, 2026$18.47$18.68$17.84$18.52282.98K
Oct 2, 2026$18.75$18.8169$17.93$18.52337.99K
Oct 1, 2026$19.41$20.08$18.31$18.52305.21K
Sep 30, 2026$19.83$19.87$19.23$19.47277.27K
Sep 29, 2026$19.30$19.725$19.06$19.69194.72K
Sep 28, 2026$19.24$19.455$19.05$19.35223.2K
Sep 25, 2026$19.71$19.81$18.965$19.43518.91K
Sep 24, 2026$19.74$20.45$19.43$19.63384.97K
Sep 23, 2026$21.87$21.87$19.67$19.72589.44K
Sep 22, 2026$21.69$22.2225$21.45$22.11302.01K
Sep 21, 2026$22.06$22.06$20.7501$21.43614.26K
Sep 18, 2026$22.86$23.085$21.875$21.882.73M
Sep 17, 2026$23.04$23.97$22.445$22.86500.88K
Sep 16, 2026$22.48$22.9428$21.31$22.71855.05K
Sep 15, 2026$23.21$23.21$22.18$22.41290.43K
Sep 14, 2026$23.36$23.705$22.79$23.17330.08K
Sep 11, 2026$24.36$24.54$23.25$23.30228.58K
Sep 10, 2026$23.80$24.355$23.57$23.94263.62K
Sep 9, 2026$25.57$26.00$24.03$24.06377.36K
Sep 8, 2026$26.99$26.99$24.23$25.02567.43K

Latest AKTS news

The latest Smart Investors Daily articles mentioning AKTS.

Stock researchCompany · Overview

AKTS research

Overview

Company profile and research snapshot.

Company profile

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.92
Implied upside
—
Analysts
—
AKTS recent ratings
DateFirmRatingTarget
Oct 2, 2026WedbushOutperform—
Sep 9, 2026OppenheimerOutperform—
Aug 19, 2026WedbushOutperform—
Aug 19, 2026BMO CapitalOutperform—
Jul 14, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3

Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumorsEnrollment is ongoing in the Phase 1b BActinium-1 clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); preliminary data expected in 2027 BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potentia

Yahoo · Sep 9, 2026

Aktis Oncology to Present at Upcoming September Investor Conferences

BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will participate in the following investor conferences in September. Morgan Stanley 24th Annual Global Healthcare C

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By